Brand Name
Corvert
Generic Name
Ibutilide
View Brand Information FDA approval date: December 28, 1995
Classification: Antiarrhythmic
Form: Injection
What is Corvert (Ibutilide)?
CORVERT Injection is indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm. Patients with atrial arrhythmias of longer duration are less likely to respond to CORVERT. The effectiveness of ibutilide has not been determined in patients with arrhythmias of more than 90 days in duration.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment